• ALS Therapy Radicava Seen to Uphold Benefits Over Nearly a Year in Extension Trial, Says MT Pharma
  • Masitinib Phase 3 Trial Data Show Slowed Amyotrophic Lateral Sclerosis Progression, AB Science Says
  • Researchers Identify New Gene Mutation Likely Involved in ALS Development
  • Israel’s BrainStorm Initiates Technology Transfer to City of Hope for NurOwn ALS Phase 3 Study
  • AB Science’s Studies of Masitinib for ALS Not Affected by EMA Inspection
  • Gene Therapy to Strengthen Nerve-Muscle Connection Prevents ALS Progression in Mice
  • Dutch Bros. Coffee Raises Nearly $1 Million to Honor Co-founder Who Died of ALS
  • Roll on Capitol Hill to Push for Greater Access to Wheelchairs for Those with Spinal Disorders
  • New Antibody Armanezumab May Be Possible Therapeutic Strategy for ALS
  • FDA Approves Radicava, First New ALS Therapy in 22 Years
  • ALS Ride for Life Marks 20th Anniversary of Raising Awareness and Funds
  • Defective RNA Processing and Protein Folding May Promote ALS, Lab Study Suggests